PharmiNews

Directory of Pharma Companies and News

Company Profile

Modus Therapeutics AB

Modus Therapeutics AB logo
Category
Modus Therapeutics is a Swedish biotech company developing sevuparin - a new drug to treat people suffering from sickle cell disease (SCD) – a painful, inherited blood disorder affecting millions of people around the globe. Sickle cell disease patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain and the amount of time they will need to spend in hospital and is currently recruiting for a Phase II clinical study. Modus plans to develop an administration form of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care.

Modus is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are The Foundation for Baltic and European Studies (Östersjöstiftelsen) and Praktikerinvest AB.

Keywords:
0 results
Brought to you by PharmiWeb.com - Latest Jobs in Pharma